ReachMD Your single destination for free CMEs, medical news, & more. Be Part of the Knowledge. The compelling broadcast line-up of information and education runs 24/7.

ReachMD is a revolutionary healthcare communications and education network dedicated to helping busy healthcare professionals stay abreast of clinical research, treatment advances, expert opinions, and patient care strategies. Our unique, integrated network leverages peer-to-peer dialogs among medical experts to educate and inform listeners across a wide spectrum of topics. Listeners can 'tune in'

to dialogs on iHeart Radio and TuneIn, enjoy online streaming radio, download podcasts, participate in web-enabled segments on ReachMD.com, and access content through the MedicalRadio mobile app. ReachMD's popular format of peer-to-peer dialogs among medical experts hits the mark for busy clinicians: segments are succinct and typically run for 15 minutes, making it convenient for listeners to participate throughout the day and night wherever they are. Both certified and non-certified education are broadcast, with unique mobile access interfaces to receive CME credit. The custom series and medical industry features are the highlight of our platform, and more than 60 unique series cycle through our programming line-up, including Diabetes Discourse™, Lipid Luminations™, CDC Updates, NEJM Summaries, Grand Rounds Nation®, The FDA Voice, Medical Breakthroughs from Penn Medicine, Heart Matters, Women's Health Fridays™, and many more. ReachMD has the brightest minds today in broadcast media. We are healthcare media strategists and healthcare educationalists whose combined expertise makes the ReachMD broadcast network a one-of-a-kind healthcare enterprise.

06/18/2026

Which breast cancer findings from ASCO 2026 are most relevant to your practice?

ASCO 2026 featured important research that may influence care across a range of patient populations. In this video brief, Dr. Aditya Bardia highlights notable studies, discusses their clinical implications, and explores how emerging data may inform treatment decision-making and patient care.

Explore the clinical implications of the latest breast cancer research: https://ow.ly/qkC550ZejxP

Could emerging therapies have a role in maladaptive FSGS? This discussion explores how therapies under review may extend...
06/18/2026

Could emerging therapies have a role in maladaptive FSGS?

This discussion explores how therapies under review may extend beyond primary FSGS to what is now referred to as maladaptive FSGS. Early observations suggest potential applicability, highlighting an area of interest for future clinical use.

Explore how these insights may shape patient care: https://ow.ly/vs0p50YFHB0

Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that...

Biomarker-guided decision-making remains central to individualized ovarian cancer care. Join this broadcast for expert d...
06/17/2026

Biomarker-guided decision-making remains central to individualized ovarian cancer care. Join this broadcast for expert discussion on treatment selection, sequencing strategies, and adverse event management across the care continuum.

Register now: https://ow.ly/HW4L50ZcPIt

06/16/2026

Is maladaptive FSGS an important target for emerging treatments?

Previously categorized as secondary FSGS, maladaptive FSGS represents a significant patient population. This program discusses how therapies under review may have relevance in this group based on early observations.

Learn more about evolving perspectives in FSGS: https://ow.ly/UN6950Zcqr9

Tomorrow: Join Dr. Marc Oliva live as he dives into clinical evidence, treatment sequencing, and multidisciplinary coord...
06/16/2026

Tomorrow: Join Dr. Marc Oliva live as he dives into clinical evidence, treatment sequencing, and multidisciplinary coordination in resectable, locally advanced head and neck squamous cell carcinoma.

Register now: https://ow.ly/6ZAk50Zb95f

Don't miss the remaining two dates for a live broadcast on treating early symptomatic Alzheimer's disease. Faculty discu...
06/15/2026

Don't miss the remaining two dates for a live broadcast on treating early symptomatic Alzheimer's disease. Faculty discuss standardized processes for therapy initiation, ARIA risk mitigation, and MRI-based monitoring to support safe and consistent care. This is a Worldwide Webinar Series, with subtitles available in French, Spanish, German, and Portuguese! Wherever you're located, we have an opportunity for you to join: https://ow.ly/Js5U50Z4q2j

06/15/2026

Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives

Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape...
06/14/2026

Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape evolving treatment strategies in resectable, locally advanced HNSCC. He'll cover patient selection, sequencing approaches, multidisciplinary care integration, and more. Register now: https://ow.ly/sxiG50Zb7Xk

06/12/2026

Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations

How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk aft...
06/11/2026

How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk after neoadjuvant treatment? The phase 3 DESTINY-Breast05 trial compared T-DXd with T-DM1 and helped inform updated NCCN guidance.

Explore the data in this video brief from ASCO 2026: https://ow.ly/SqlJ50ZabNV

Address

1301 Virginia Drive Ste 300
Fort Washington, PA
19034

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Alerts

Be the first to know and let us send you an email when ReachMD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share